Recent News
Dr. Arthur Kavanaugh and Dr. Eric Ruderman gave an update on what's new in spondyloarthritis at the 2026 Rheumatology Winter Clinical Symposium (RWCS) in Maui, Hawaii. Here's a summary.Read Article
Prevention in Lupus and Therapeutic Evolution in Sjögren’s
The notion of intervening in autoimmune disease prior to the onset of irreversible tissue damage has evolved beyond a theoretical framework; it is presently undergoing empirical evaluation. Recent discussions on incomplete lupus and the SMILE trial, alongside advances in Sjögren’s therapeutics, highlight both the promise and complexity of prevention and precision treatment in systemic autoimmunity.
Read Article
RT @richardPAConway
The new kid on the block in RA-ILD (and other PPF). Nerandomilast, an anti-fibrotic with additional anti-inflammatory/immunomodulating functions. Demonstrated significant mortality benefit in ILD. #RNL26 https://t.co/8DU3WyPQGy
Dr. John Cush @RheumNow ( View Tweet)
RT @RichardPAConway
ACR/Chest and EULAR/ERS guidelines for RA-ILD presented by Dr Sparks. I'm posting the one I use ;) #RNL26 https://t.co/a6vwQWbjE7
Dr. John Cush @RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Paradoxical psoriasis with TNF
Highest in infliximab
Seen highest in IBD, particular Crohn's
Palmopustular is most common manifestation
May have overlap appearance with psoriaform with eczema, histology with psoriaform spongiotic dermatosis with https://t.co/SKQZgbLQUS
Dr. John Cush @RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Prosthetic joint infection vs flare?
- PJI risk 50-80% higher in RA (OR 1.47-1.8)
- Immunosuppressants, intra-artic injections, RA activity, BMI incr risk
- Delay in diagnosis https://t.co/XTozafDQyf
Dr. John Cush @RheumNow ( View Tweet)
What did you miss at RheumNow Live 2026?
Our Poster Hall features new data across:
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• Lupus Nephritis
• Vasculitis
• Polymyalgia Rheumatica
• Axial Spondyloarthritis
From Phase III trials to real-world evidence, these
Dr. John Cush @RheumNow ( View Tweet)
Spectrum of skin Sxs in 518 pts w/ Stills dz from AutoInflammatory Dz Alliance (AIDA) Network Registry dedicated to Still’s disease includes Salmon evanescent rash (64%), macules (7.7%), urticaria (6%), persistent pruritic papules & plaques (PPPP) (4.8%) https://t.co/DW9NoaxNPP https://t.co/U5GrCutYT0
Links:
Dr. John Cush @RheumNow ( View Tweet)
FDA has Changed labels for 6 Menopausal Hormone Therapies (HRT) removing black box warnings for CV dz, breast CA, & dementia. 1st six HRTs includes estrogen-& progestogen-only Rx:Prometrium, Divigel, Cenestin, Enjuvia, & combo Rx Bijuva, & topical Estring. https://t.co/ZpcKkzYPKn https://t.co/f9XbmlKZNo
Dr. John Cush @RheumNow ( View Tweet)
Maui Potpourri (2.13.2026)
Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow Live 2026.
https://t.co/ieRhIVZb2D https://t.co/KaYtSnHUIL
Links:
Dr. John Cush @RheumNow ( View Tweet)
RT @gibson_rheumPAC
Given rising resistance, effective first-line regimens and adequate duration (14 days) are critical. PPI-based quadruple regimens remain highly effective when patients can adhere.
#RNL26 https://t.co/rQps2rls8G
Dr. John Cush @RheumNow ( View Tweet)
RT @gibson_rheumPAC
Who should be tested?
Test only if you plan to treat.
Indications include:
• Active or prior ulcers
• MALT lymphoma
• Gastric cancer
• Chronic atrophic gastritis
Avoid indiscriminate testing.
#RNL26 atoid arthritis https://t.co/2KJluSAPNx
Dr. John Cush @RheumNow ( View Tweet)
Genentech announced results of Phase III, MAJESTY OL study of obinutuzumab vs tacrolimus in 142 pts w/ primary membranous nephropathy & found signif more complete remissions at 2 yrs in obintuzumab Rx pts. Obintuzumab (Gazyva) if FDA approved for lupus nephritis. https://t.co/maJbvUCkBe
Dr. John Cush @RheumNow ( View Tweet)
Screening study of lung US (LUS) vs HRCT in 73 RA pts (DAS28 3.47) Chest HRCT identified ILD in 29%. LUS identified ILD in 22% of patients. LUS sensitivity was 59%; specificity 94%. ROC. This study demonstrates the good diagnostic performance of LUS in RA- ILD detection https://t.co/E8avnbvUiw
Dr. John Cush @RheumNow ( View Tweet)
Rotator cuff abnormalities are nearly universal after age 40, & incr w/ age; routine imaging should not guide Dz or Tx of atraumatic shoulder pain. Study of 602 having MRI (58yrs) RC abnormalities in 98.7%;; 25% tendinopathy, 62% Partial & 11% Full thickness tears https://t.co/Jw9rMUQBLs
Dr. John Cush @RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Arthroplasty risks in RMD
AxSpA - Respiratory complications (OR 1.7), PNA (2.2)
SLE - complications ass w/ severity/activity. Renal failure, PE, sepsis, stroke, mortality depending on activity
PsA - complications related to co-morbidities, not PsA https://t.co/jr0hwh3CPe
Dr. John Cush @RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Inflammatory arthritis pts getting TKA:
- increased risk of RBC transfusion (OR 1.39), infection (1.64) and readmission (1.46)
- THA: also risk of mechanical complications (like dislocation) OR 1.3 https://t.co/ovW2C2EuXF
Dr. John Cush @RheumNow ( View Tweet)
RT @RichardPAConway
UIP pattern RA-ILD is where the big problem is. We are less good at treating this. Perhaps the newer agents such as nerandomilast will change this? #RNL26 https://t.co/Z0BXxyNrCI
Dr. John Cush @RheumNow ( View Tweet)
RNL 26 Report: Spondyloarthritis
Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, about lectures presented during the "Staying Ahead of Spondyloarthritis" session.
https://t.co/UjvauWoga5 https://t.co/Zv8dmUuVyD
Dr. John Cush @RheumNow ( View Tweet)
Obesity, Surgery, and Optimizing Patient Care
Rheumatologic care requires a multidisciplinary approach and collaboration with other specialties to treat complex systemic diseases. While many Pods at RheumNow Live are disease-specific, the Pod II focused on Advancing Practice on https://t.co/hvSY5yHZmd
Dr. John Cush @RheumNow ( View Tweet)
From the Blog
Podcasts
Maui Potpourri (2.13.2026)-
ANA Pollution (2.06.2026)
DERM on RheumNow PODCAST (January 2026)-
RheumNow Live Preview (1.30.2026)
Therapeutic Updates
The Impact of Obesity on Psoriatic Arthritis
Sponsored by Lilly Medical Affairs
Image alt text: A person indoors raises one arm in a flexed pose while holding the elbow with the opposite hand.
Is obesity common in your patients with PsA? Learn more about the intersection of disease pathogenesis between PsA and obesity and how weight intervention can affect PsA outcomes.
Read Post
Poster Hall
